GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (STU:IL3) » Definitions » Research & Development

Integra Lifesciences Holdings (STU:IL3) Research & Development : €107 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Integra Lifesciences Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Integra Lifesciences Holdings's Research & Development for the three months ended in Dec. 2024 was €30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €107 Mil.


Integra Lifesciences Holdings Research & Development Historical Data

The historical data trend for Integra Lifesciences Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Research & Development Chart

Integra Lifesciences Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.61 82.35 95.53 95.54 110.19

Integra Lifesciences Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.27 24.81 27.65 24.72 29.81

Integra Lifesciences Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €107 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings  (STU:IL3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Integra Lifesciences Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Integra Lifesciences Holdings Headlines

No Headlines